WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene

Giorgia Montano¹,², Karina Vidovic², Chiara Palladino¹, Elena Cesaro¹, Gaetano Sodaro¹, Concetta Quintarelli³, Biagio De Angelis³, Santa Errichiello³, Fabrizio Pane³, Paola Izzo¹, Michela Grosso¹, Urban Gullberg² and Paola Costanzo¹

¹ Department of Molecular Medicine and Medical Biotechnology University of Naples Federico II, Naples, Italy
² Department of Haematology and Transfusion Medicine, BioMedical Center, Lund University, Lund, Sweden
³ Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

Correspondence to: Paola Costanzo, email: paola.costanzo@unina.it

Keywords: ZNF224, chronic myeloid leukemia, BCR-ABL, WT1, tyrosine kinase inhibitors

Received: March 23, 2015  Accepted: July 08, 2015  Published: July 22, 2015

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The Kruppel-like protein ZNF224 is a co-factor of the Wilms’ tumor 1 protein, WT1. We have previously shown that ZNF224 exerts a specific proapoptotic role in chronic myelogenous leukemia (CML) K562 cells and contributes to cytosine arabinoside-induced apoptosis, by modulating WT1-dependent transcription of apoptotic genes. Here we demonstrate that ZNF224 gene expression is down-regulated both in BCR-ABL positive cell lines and in primary CML samples and is restored after imatinib and second generation tyrosine kinase inhibitors treatment. We also show that WT1, whose expression is positively regulated by BCR-ABL, represses transcription of the ZNF224 gene. Finally, we report that ZNF224 is significantly down-regulated in patients with BCR-ABL positive chronic phase-CML showing poor response or resistance to imatinib treatment as compared to high-responder patients. Taken as a whole, our data disclose a novel pathway activated by BCR-ABL that leads to inhibition of apoptosis through the ZNF224 repression. ZNF224 could thus represent a novel promising therapeutic target in CML.

INTRODUCTION

The Kruppel-like zinc-finger protein ZNF224 was initially identified as the transcriptional repressor of the human aldolase gene [1]. Similarly to other zinc finger proteins containing the KRAB repressor domain, ZNF224 recruits, through its KRAB domain, the KAP1 co-repressor complex containing histone deacetylases and enzyme activities modulating chromatin to repress gene transcription [2, 3]. The arginine methyltransferase type II, PRMT5, was identified as an additional component of the ZNF224 transcriptional repression complex, which mediates methylation of arginine 3 of histone H4 in the nucleosomes surrounding the promoter region, thus eliciting the repression of gene expression [4].

More recently, our findings have highlighted the role of ZNF224 as a transcriptional co-factor of the Wilms’ tumour protein 1, WT1, that is achieved through the interaction of ZNF224 with the WT1(-KTS) isoform [5]. WT1 plays an oncogenic role in a wide range of solid tumors and hematopoietic malignancies, including chronic myelogenous leukemia (CML) [6-8]. More in detail, WT1 exerts anti-apoptotic functions in leukemic cells by controlling the expression of several apoptotic genes, including proapoptotic bcl-2 family members [9, 10] and the anti-apoptotic genes A1/Bfl-1 [11] and bag3 [12]. In a previous study we were able to demonstrate that ZNF224 acts as a co-activator of WT1(-KTS) in the regulation of proapoptotic genes and suppresses WT1-mediated transactivation of antiapoptotic genes in the CML-derived cell line K562, thus pointing to a role for ZNF224/WT1(-KTS) interaction in leukemia. We also demonstrated that ZNF224 plays a relevant role in ara-C-induced apoptosis of leukemia cells [13].

CML is a myeloproliferative disorder characterized by the BCR-ABL gene rearrangement. The BCR-ABL oncoprotein possesses an ABL tyrosine kinase domain that is constitutively activated [14] and supports malignant...
trasformation by activating multiple signal transduction pathways that promote uncontrolled cell proliferation [15], abnormal cell adhesion [16] and resistance to many apoptotic stimuli induced by antileukemic drugs [17, 18]. Nevertheless, the antiapoptotic pathways triggered by BCR-ABL are still poorly understood.

Our previous findings prompted us to investigate the effects of imatinib and second generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib on ZNF224 expression levels and to identify the molecular mechanisms of ZNF224 down-regulation in CML cells. In this study we demonstrate that inhibition of BCR-ABL tyrosine kinase activity, induced by imatinib, triggers the up-regulation of ZNF224 expression at the transcriptional level. Moreover, we show that WT1 is involved in the transcriptional repression of ZNF224 in BCR-ABL expressing cells, in accordance with a recent finding indicating that WT1 is a BCR-ABL survival factor and its expression is induced via the phosphatidylinositol-3 kinase (PI3K)-Akt pathway [19]. Finally, we found a correlation between ZNF224 mRNA expression levels and responsiveness to imatinib therapy in patients with BCR-ABL positive chronic phase CML (CP-CML). This suggests that ZNF224 could be exploited as a novel predictive factor for imatinib response in CML patients.

RESULTS

ZNF224 expression is down-regulated in BCR-ABL positive cell lines and CD34+ primary cells derived from CML patients

To address whether BCR-ABL expression is associated with down-regulation of ZNF224, we initially measured ZNF224 mRNA levels in leukemia cell lines (K562, BV173, LAMA84) derived from CML patients, in CD34+ primary bone marrow cells derived from 10 CML patients at diagnosis, all characterized by the presence of BCR-ABL fusion gene, or in BCR-ABL negative cell lines (KG1, UT7) derived from patients with acute myeloid leukemia (AML). As shown in Figure 1, the expression levels of ZNF224 were significantly lower in BCR-ABL positive cell lines as well as in CD34+ primary cells from CML patients with respect to BCR-ABL negative cell lines.

TKIs induce expression of ZNF224 in BCR/ABL positive cell lines

To investigate the functional activity of BCR-ABL on ZNF224 expression, we treated K562 cells with increasing concentrations of the tyrosine kinase inhibitor imatinib for 24, 48 and 72 h, after which annexin assay

![Figure 1: ZNF224 expression in CD34+ primary bone marrow cells from CML patients and in human myeloid leukemia cell lines.](image-url)

*Quantitative evaluation by RT-qPCR of ZNF224 mRNA expression in CD34+ primary cells collected from 10 CML patients, in BCR-ABL<sup>pos</sup> cell lines (K562, BV173, LAMA84), or in BCR-ABL<sup>neg</sup> cell lines (KG1, UT7). mRNA levels of normal human CD34+ cord blood cells were referred to as 1. Error bars represent standard deviations of two independent experiments. ****p = 0.0000017, ***p = 0.00006, **p = 0.0097, *p < 0.02.*
was performed to evaluate apoptosis, and ZNF224 mRNA levels were measured (Figure 2). As expected, annexin positivity was induced by imatinib in a dose and time-dependent manner (Figure 2a); interestingly, we observed that exposure of K562 cells to imatinib also resulted in a time and dose-dependent up-regulation of ZNF224 mRNA expression (Figure 2b). To evaluate whether ZNF224 expression was selectively induced by BCR-ABL inhibition, thus excluding that it occurred as consequence of apoptotic machinery activation, we treated K562 cells with topoisomerase inhibitors etoposide and camptothecin and with a PKC inhibitor, staurosporine. As expected, treatment with each of these three drugs induced apoptosis, as revealed by the increased annexin-V binding (Figure 2c), whereas no upregulation of ZNF224 expression was observed (Figure 2d), thus indicating that ZNF224 expression is specifically related to BCR-ABL inhibition.

To provide additional evidence that BCR-ABL signaling represses ZNF224 expression we used the BCR-ABLpos cell line KCL22-S and its imatinib-resistant counterpart KCL22-R. These resistant cells are no longer

![Graph A: Annexin V binding in imatinib-treated K562 cells](image)

![Graph B: ZNF224 mRNA levels in imatinib-treated K562 cells](image)

![Graph C: Annexin V binding and ZNF224 mRNA levels in drug-treated K562 cells](image)

**Figure 2: ZNF224 expression in drug-treated K562 cells.** K562 cells were exposed to increasing concentration of imatinib (0.3 µM, 0.6 µM, 1 µM, 3 µM) or vehicle only (DMSO) as control and analyzed after 24, 48 and 72h. **a.** Apoptosis was determined by annexin V-APC staining followed by flow cytometry. Results represent the mean +/- SD of three independent experiments. **b.** ZNF224 mRNA levels were measured by RT-qPCR. Relative amounts as compared to control are shown. Error bars represent standard deviations of three independent experiments. **c, d.** K562 cells were treated with 20 µM Etoposide (ETO), 10 µg/ml Camptothecin (CPT), 5 µM Staurosporine (STS) or vehicle only (DMSO) as control and analyzed for apoptosis as determined by Annexin V-APC staining followed by flow cytometry (c) and ZNF224 mRNA levels as determined by RT-qPCR analysis (d) after 24 and 48h. Results represent the mean +/- SD of two independent experiments.
dependent on oncogenic BCR-ABL kinase activity for survival, and thus imatinib at high concentration (5 μM) suppresses BCR-ABL activity, without affecting their viability [20]. KCL22-S and KCL22-R cells were treated with 5 μM imatinib for 48h after which apoptosis and ZNF224 expression were analyzed. As expected, imatinib was able to induce annexin positivity only in the sensitive (Figure 3a), and not in the resistant KCL22 cell line (Figure 3c). On the contrary, imatinib was able to induce ZNF224 mRNA expression (Figure 3b and 3d) and ZNF224 protein (Figure 3e and 3f) in both cell lines, correlating to suppression of BCR-ABL activity in both sensitive and resistant cells [20]. We then investigated whether ZNF224 mRNA expression is also modulated by the second-generation TKIs, dasatinib and nilotinib. To this aim, we exposed KCL22-S and KCL22-R cell lines to either dasatinib or nilotinib (0.03 μM and 0.4 μM, respectively) for 48 h. We found that both compounds were able to induce apoptosis only in the sensitive but not in the resistant cell line (Figure 3a and 3c), whereas, similarly to the imatinib treatment, ZNF224 mRNA expression was induced in both KCL22-S and KCL22-R cell lines (Figure 3b and 3d). Western blot analysis confirmed the induction of ZNF224 protein by dasatinib and nilotinib in both KCL22-S and KCL22-R cells (Figure 3e and 3f). These findings further strengthen the conclusion that increased ZNF224 expression follows inhibition of BCR-ABL signaling, rather than being a non-specific consequence of apoptosis induction. It is to be noted that inhibition of the BCR-ABL kinase activity

Figure 3: Effects of imatinib and second-generation TKIs on ZNF224 expression in KCL22 CML cell lines. KCL22S (a, b, e) and KCL22R (c, d, f) cells were treated with 5 μM imatinib, 0.03 μM dasatinib or 0.4 μM nilotinib or vehicle only (DMSO) as control for 48h. a., c. Apoptosis was determined by annexin V-APC staining followed by flow cytometry. Results represent the means +/- SD of two independent experiments. b., d. ZNF224 mRNA levels were measured by RT-qPCR. Error bars represent standard deviations of two independent experiments. e., f. Western blot analysis of ZNF224 in KCL22S (e) and KCL22R (f). β-tubulin was used as loading control. Molecular weight to the left. One representative blot out of two performed is shown.
**Figure 4: Role of BCR-ABL in ZNF224 down-modulation.** BCR-ABL\textsuperscript{pos} K562 cells (a, c, e) and BCR-ABL\textsuperscript{neg} KG1 cells (b, d, f) were exposed to 3 µM imatinib or vehicle only (DMSO) as control for 24, 48 and 72h. a, b. Apoptosis was determined by annexin V-APC staining followed by flow cytometry. Results represent the mean +/- SD of two independent experiments. c, d. Quantitative evaluation by RT-qPCR of ZNF224 mRNA expression in K562 and KG1 cells. Error bars represent standard deviations of two independent experiments. e, f. Western blot analysis of ZNF224 in K562 and KG1 cells; C: cells treated with DMSO for 72h used as control. GAPDH was used as loading control. One representative blot out of two performed is presented. g. Quantitative evaluation by RT-qPCR of ZNF224 and WT1 mRNA expression levels in KG1 cells transfected for 48h with BCR-ABL expression vector or pcDNA3 empty vector as control. Error bars represent standard deviations of two independent experiments. h. Western blot analysis of ZNF224 and WT1 in KG1 cells transfected for 48h with BCR-ABL expression vector or pcDNA3 empty vector as control. GAPDH was used as loading control. Molecular weight to the left. One representative blot out of two performed is presented.
and the resulting increase of ZNF224 in the resistant 
KCL22-R cell line are not sufficient to induce apoptosis, 
thus indicating that concomitant mechanisms, hampering 
the expected cell death increase, are responsible for the 
resistance to apoptosis in these cells.

Expression of BCR-ABL in KG1 cell line down-
regulates ZNF224 expression

To confirm that ZNF224 increase is specifically 
related to BCR-ABL inhibition, we exposed K562 (BCR-
ABL<sup>pos</sup>) and KG1 (BCR-ABL<sup>neg</sup>) cells to 3 µM imatinib for 
24, 48 and 72h. As expected, imatinib-treatment induced 
apoptosis in BCR-ABL positive K562 cells (Figure 4a), 
but not in the BCR-ABL negative KG1 cells (Figure 4b).

Similarly, ZNF224 induction both at mRNA and protein 
level was observed only in imatinib-treated K562 cells 
(Figure 4c and 4e) and not in imatinib-treated KG1 cells 
(Figure 4d and 4f).

To definitively prove the role of BCR-ABL in down-
regulation of ZNF224 expression, we transfected KG1 
cells with an expression vector encoding human BCR-
ABL and with empty vector as control. Ectopic expression 
of BCR-ABL in KG1 strongly reduced ZNF224 both at 
mRNA (Figure 4g) and protein levels (Figure 4h). As 
shown, a considerable increase in WT1 expression was 
observed in response to BCR-ABL (Figure 4g and 4h), 
consistent with a previous study showing that the tyrosine 
kirnase activity of BCR-ABL signals increases expression 
of WT1 (19).

Figure 5: Imatinib enhances ZNF224 mRNA expression via transcriptional mechanism. a. K562 cells were treated with 1 
µM imatinib or vehicle only (DMSO) as control for 48h after which 4 µg/ml actinomycin D was added to block de novo mRNA synthesis. 
ZNF224 mRNA levels were determined by RT-qPCR 0.5, 1, 3, 5 and 7h after addition of actinomycin D. Error bars represent standard 
deviations of three independent experiments. b. Schematic representation of the reporter plasmid containing the ZNF224 promoter region 
(-1000 to +141) used in transient transfection experiments (promZNF224). c. K562 cells were transfected with promZNF224 for 24h, after 
which cells were incubated with 1 µM imatinib for 24 and 48h or vehicle only (DMSO) as control, for 48h. The promoter activity was 
measured by normalizing firefly to renilla luciferase activity. pGL3Luc null empty vector activity indicates the background. Data shown are 
the mean values +/-S.D. of three independent experiments, each of which included triplicate determinations.
All together, these data demonstrate that imatinib could hamper a BCR-ABL signaling-dependent mechanism of ZNF224 repression.

**Imatinib enhances ZNF224 mRNA expression via transcriptional activation**

We next determined whether the induction of ZNF224 mRNA expression by imatinib is a result of altered ZNF224 mRNA stability. K562 cells were incubated for 48 h with or without 1 µM imatinib after which actinomycin D was added to block *de novo* mRNA synthesis. After addition of actinomycin D, the decay of ZNF224 mRNA was monitored by repeated real time RT-PCR analyses. Pretreatment with imatinib did not increase the stability of ZNF224 transcript rather it was slightly decreased, as indicated by a somewhat more rapid decline following actinomycin D addition (Figure 5a). The same analysis was performed in K562 cells incubated with 1 µM imatinib for 24 h (data not shown). These results indicate that imatinib modulates ZNF224 mRNA expression by transcriptional activation of the ZNF224 gene. To demonstrate transcriptional effects, K562 cells were transiently transfected with the ZNF224 promoter cloned in a luciferase reporter plasmid (promZNF224) (Figure 5b), and then treated with 1 µM imatinib for 24 and 48 h. As shown in Figure 5c, the basal ZNF224 promoter activity was increased upon exposure to imatinib. In contrast, imatinib showed no effect on pGL3-control promoter (Figure 5c). On the basis of these experiments, we conclude that imatinib, via inhibition of BCR-ABL tyrosine kinase activity, increases ZNF224 expression through a transcriptional mechanism.

**WT1 represses ZNF224 gene expression**

Subsequently, to search for transcription factors potentially involved in ZNF224 regulation downstream of BCR-ABL signaling, we conducted an *in silico* analysis of putative transcription factor binding sites located in the ZNF224 promoter. Interestingly, three WT1 binding sites surrounding the ZNF224 transcription start site were found. According to the fact that BCR-ABL induces WT1 expression [19] whereas ZNF224 is down-modulated by BCR-ABL (see Figure 3), we evaluated whether WT1 could be involved in the transcriptional suppression of ZNF224 mediated by BCR-ABL. To verify WT1 occupancy on the ZNF224 promoter and the effects of imatinib on this binding, we conducted Chromatin immunoprecipitation assays (ChIP) in K562
cells incubated for 24h in the presence or absence of imatinib. Chromatin was immunoprecipitated with a WT1 antibody and real time PCR analysis was performed using specific ZNF224 primers, covering the 3 putative WT1 binding sites on ZNF224 promoter region (-161 to +144). PIM1 was used as negative control. Error bars indicate the mean value +/- SD of two independent experiments. b. K562 cells were transfected with promZNF224 together with 0.25 µg and 0.5 µg of WT1(-KTS) expression plasmid or with 0.5 µg of empty pcDNA3 as control. After 48h, promoter activity was determined by normalizing firefly to renilla luciferase activity. Shown is promoter activity relative to that of promZNF224 in control cells (mean values +/-S.D., three independent experiments). c. Western blot analysis of ZNF224 and WT1 proteins in cell lysates of K562 cells transfected with 0.25 µg or 0.5 µg of WT1(-KTS) expression plasmid for 48h. GAPDH was used as loading control. Molecular weights to the left. One representative result out of two performed is presented. d. K562 cells transduced with two different shRNAs targeting WT1 (shWT1 N°1 and shWT1 N°2) or a scrambled control were transfected with promZNF224 for 48h. Promoter activity was determined by normalizing firefly to renilla luciferase activity. Shown is promoter activity relative to that of promZNF224 in cells transduced with a scrambled control (mean values +/-S.D., three independent experiments). *P = 0.03; **P = 0.0006. e. Western blot analysis of WT1 protein levels in K562 cells transduced with shWT1 N°1, shWT1 N°2 or a scrambled control. GAPDH was used as loading control. f. K562 cells were transfected with promZNF224 with or without 0.5 µg of WT1(-KTS) expression plasmid or 0.5 µg of pcDNA3 as control. 24h after transfection, the cells were incubated for 48 h in the presence of 1 µM imatinib, after which promoter activity was measured by normalizing firefly to renilla luciferase activity. Shown is promoter activity relative to that of promZNF224 in control cells (mean values +/-S.D., three independent experiments) p < 0.05.

Figure 6: WT1(-KTS) binds to the ZNF224 promoter and represses ZNF224 expression. a. K562 cells were treated with 1 µM imatinib or vehicle only (DMSO) as control for 24h after which chromatin immunoprecipitation assay was performed with an anti-WT1 antibody (C19). Immunoprecipitation with non-specific IgG was used as negative control. Quantitative real time PCR analysis was performed using specific ZNF224 primers, covering the 3 putative WT1 binding sites on ZNF224 promoter region (-161 to +144). PIM1 was used as negative control. Error bars indicate the mean value +/- SD of two independent experiments. b. K562 cells were transfected with promZNF224 together with 0.25 µg and 0.5 µg of WT1(-KTS) expression plasmid or with 0.5 µg of empty pcDNA3 as control. After 48h, promoter activity was determined by normalizing firefly to renilla luciferase activity. Shown is promoter activity relative to that of promZNF224 in control cells (mean values +/-S.D., three independent experiments). c. Western blot analysis of ZNF224 and WT1 proteins in cell lysates of K562 cells transfected with 0.25 µg or 0.5 µg of WT1(-KTS) expression plasmid for 48h. GAPDH was used as loading control. Molecular weights to the left. One representative result out of two performed is presented. d. K562 cells transduced with two different shRNAs targeting WT1 (shWT1 N°1 and shWT1 N°2) or a scrambled control were transfected with promZNF224 for 48h. Promoter activity was determined by normalizing firefly to renilla luciferase activity. Shown is promoter activity relative to that of promZNF224 in cells transduced with a scrambled control (mean values +/-S.D., three independent experiments). *P = 0.03; **P = 0.0006. e. Western blot analysis of WT1 protein levels in K562 cells transduced with shWT1 N°1, shWT1 N°2 or a scrambled control. GAPDH was used as loading control. f. K562 cells were transfected with promZNF224 with or without 0.5 µg of WT1(-KTS) expression plasmid or 0.5 µg of pcDNA3 as control. 24h after transfection, the cells were incubated for 48 h in the presence of 1 µM imatinib, after which promoter activity was measured by normalizing firefly to renilla luciferase activity. Shown is promoter activity relative to that of promZNF224 in control cells (mean values +/-S.D., three independent experiments) p < 0.05.
lentiviral shRNAs targeting WT1 or a scrambled control. Following transfection with promZNF224 we found that WT1 knockdown leads to a considerable increase in promZNF224 luciferase activity (Figure 6d).

Finally, to evaluate the role of WT1 on the imatinib-mediated induction of ZNF224 promoter activity, K562 cells were transfected with promZNF224 alone or co-transfected with the expression vector for WT1(-KTS) and treated with imatinib for 48h. As shown in Figure 6f, WT1 over-expression effectively counteracts the induction of ZNF224 promoter activity elicited by imatinib. These results, in agreement with ChIP data, provide further evidence that WT1 is an effector of the ZNF224 transcriptional repression induced by BCR-ABL.

**BCR-ABL-mediated suppression of ZNF224 occurs via the PI3K-Akt signaling pathway**

The phosphatidylinositol-3 kinase (PI3K)-Akt pathway is one of the three major signaling pathways constitutively activated by the BCR-ABL tyrosine kinase activity [21, 22] and it has been shown to mediate the BCR-ABL-induced upregulation of WT1 expression [19]. Therefore, we expected that also suppression of ZNF224

---

**Figure 7: BCR-ABL decreases ZNF224 expression via PI3K-Akt signaling pathway.**

a. K562 cells were treated for 16h with 1 µM Imatinib, or 30 µM PI3K inhibitor (LY294002), or 20 µM dual PI3K/AKT/mTOR inhibitor (BEZ235), or 50 ng/ml mTOR inhibitor (Rapamycin) or 1 µM mTOR inhibitor (Everolimus) or vehicle only (DMSO) as control. ZNF224 and WT1 mRNA levels were measured by RT-qPCR. Error bars represent standard deviations of three independent experiments.  

b. Protein extracts were subjected to Western blotting with antibodies against phospho-Akt (Ser473), total Akt, phospho-p70 S6-kinase and total p70 S6-kinase. GAPDH was used as loading control. One representative blot out of two performed is presented. Molecular weights to the left.  

c. K562 cells were incubated for 16h with 30 µM LY294002 or vehicle only (DMSO) as control, after which 4 µg/ml actinomycin D was added to block de novo mRNA synthesis. Cells were collected at 0, 0.5, 1, 3, 5 and 7h after addition of actinomycin D and RT-qPCR analysis of ZNF224 mRNA levels was performed. Error bars represent standard deviations of three independent experiments.
by BCR-ABL should be dependent on the PI3K-Akt pathway. To investigate this issue, K562 cells were treated for 16 h either with imatinib, PI3K inhibitor (LY294002), dual PI3K/AKT/mTOR inhibitor (BEZ235) or with the mTOR inhibitors Rapamycin and Everolimus, after which ZNF224 expression was evaluated (Figure 7a, left panel). In agreement with data shown in Figure 2b, imatinib increased the levels of ZNF224. Interestingly, ZNF224 mRNA increased following inhibition of PI3K or Akt, while mTOR inhibition did not affect ZNF224 mRNA expression, thus indicating the involvement of PI3K-Akt signaling pathway in ZNF224 suppression. According to previous results [19], we observed that inhibition of PI3K or Akt, but not mTOR, resulted in a decrease of WT1 mRNA (Figure 7a, right panel). To confirm the inhibition of the PI3K pathway by LY294002 and BEZ235, phosphorylation of Akt was analyzed by Western blot; phosphorylation of p70S6-kinase (a substrate phosphorylated by mTOR) was analyzed to confirm the efficacy of BEZ235, Rapamycin and Everolimus (Figure 7b). Furthermore, by inhibiting mRNA synthesis with actinomycin D we showed that PI3K signaling did not significantly affect the ZNF224 mRNA stability (Figure 7c), as already observed after treatment with imatinib (Figure 5a).

These data provide evidence that BCR-ABL-mediated suppression of ZNF224 expression is dependent on the PI3K pathway, via the transcriptional repression exerted by WT1 on ZNF224 gene expression.

**ZNF224 expression in patients with chronic myeloid leukemia**

Finally, we analyzed ZNF224 mRNA expression in peripheral mononuclear cells from 30 adult patients with BCR-ABL positive chronic phase CML (CP-CML) at diagnosis (Dx) and after three months (FU) of treatment with imatinib standard dose as a first-line therapy. On the basis of response at 12 months of imatinib therapy the patients were clustered in optimal responders (15 patients) and warning/failure responders (15 patients), according to the criteria of Baccarani et al. [23]. Intriguingly, as shown in Figure 8, at diagnosis ZNF224 mRNA levels in both patient cohorts were significantly lower than in healthy donors (HDs) (p < 0.0001). Furthermore, we observed a correlation between the baseline levels of ZNF224 mRNA and imatinib responsiveness. In fact, at diagnosis optimal responders showed ZNF224 mRNA levels significantly higher than warning/failure responders (p = 0.039) while at follow-up ZNF224 expression was found significantly increased in all patients. These findings indicate that higher ZNF224 levels at diagnosis could correlate with better treatment responsiveness.

**DISCUSSION**

The leukemogenic BCR-ABL fusion protein activates multiple signal transduction pathways which, in turn, may affect the expression of genes implicated in the...
pathogenesis of CML [14]. One of the key mechanisms implicated in the malignant transformation by BCR-ABL is represented by inhibition of apoptosis [21], which may be triggered through the down-modulation of different proapoptotic factors [24]. Some of these have been recently shown to be indirect transcriptional targets of the BCR-ABL oncoprotein. Expression of Bim is inhibited in BCR-ABL positive cells, due to inactivation of FoxO3a, a trans-activator of Bim. Imatinib treatment results in FoxO3a activation, induction of Bim expression and apoptosis [25]. Likewise, it has been recently demonstrated that BCR-ABL represses at transcriptional level the lymphoid-specific transcription factor BACH2 through the suppression of Pax5 expression, a potent trans-activator of BACH2 [26].

We previously showed that the zinc finger protein ZNF224 is crucial for ara-C induced apoptosis of CML cells. The pro-apoptotic effect of ZNF224 results mainly from its role as a cofactor for the transcription factor WT1; more in detail, we found that ZNF224 induction by ara-C enhances apoptosis in K562 cells through the down-regulation of antiapoptotic WT1 target genes such as bag3 and A1/Bfl1 and the upregulation of proapoptotic genes such as VDR, Bax and Bak [13]. Here we show that ZNF224 expression is down-regulated in BCR-ABL positive CML cell lines and primary CD34-enriched cells from CML patients. More interestingly, imatinib and second-generation TKIs nilotinib and dasatinib are able to specifically restore ZNF224 expression. By investigating the molecular mechanisms involved in the imatinib-dependent ZNF224 induction, we demonstrate that ZNF224 is an indirect transcriptional target of BCR-ABL. Furthermore, we have identified WT1, whose expression is induced by the oncogenic signaling triggered by BCR-ABL via the PI3K/AKT pathway [19], as a transcriptional repressor of ZNF224 in CML. Similarly, WT1 mediates BCR-ABL induced repression of the myeloid tumor suppressor IRF8 [27].

Data herein presented regarding the role of WT1 as a repressor of ZNF224 gene in CML could also contribute to explain the mechanism leading to ZNF224 induction by ara-C and the consequent apoptosis; indeed, our previous observation that ara-C induces a down-modulation of WT1 in K562 cells [13] correlates well with the ZNF224 up-regulation that we found following treatment with either ara-c or imatinib. Our data, thus, lead us to hypothesize that the distinct signaling cascades induced by ara-C and imatinib could converge on ZNF224 induction through the down-modulation of WT1. Therefore, the current study represents a further advancement with respect to our previous findings [13] and could contribute to shed light on the mechanisms of ara-C induced apoptosis, that are still largely undetermined.

In addition, our molecular data are suggestive of a regulatory loop in which WT1, by repressing the expression of ZNF224 gene, could prevent the proapoptotic effect of the ZNF224-WT1 complex itself, thus contributing to the WT1 pro-survival role in leukemia.

Similarly to our results on WT1 and ZNF224, a regulatory circuit was proposed between WT1 and Pax-2 in kidney development in which WT1 protein has been shown to inhibit the expression of Pax-2 gene [28] that, in turn, acts as a transcriptional activator of the WT1 gene [29]. Furthermore, WT1 and Pax-2 proteins are able to form a molecular complex, that could affect the transcriptional regulatory properties of the two proteins [30]. The identification of ZNF224 as a downstream target of BCR-ABL kinase activity may lead to important new insights in the molecular mechanisms underlying CML. Particularly, the development of imatinib resistance in CML patients is a dramatic issue in clinical practice, and a key topic currently addressed in CML research. Amplification of the BCR-ABL gene or point mutations within the BCR-ABL kinase domain are the most commonly identified mechanisms of resistance to imatinib [31, 32]. Our data strongly suggest that the induction of ZNF224 expression could provide promising means to circumvent imatinib resistance and to develop new therapeutic approaches in CML.

Finally, preliminary data from CML patients suggest that ZNF224 could be a novel biomarker at diagnosis to predict the imatinib sensitivity in patients with chronic myelogenous leukemia, although analysis of ZNF224 expression levels in a larger cohort of patients is required in order to assess its potential use in clinical practice.

MATERIALS AND METHODS

Cell lines

HEK293T/17 human cell lines were cultured in Dulbecco’s modified Eagle’s medium (Bio-Whittaker, Verviers, Belgium) supplemented with 10% fetal calf serum, 100 µg/ml streptomycin-penicillin mix (Bio-Whittaker) at 37°C in 5% CO2.

Acute and chronic myeloid leukemia cell lines were cultured in RPMI 1640 supplemented with 10% fetal calf serum and 100 µg/ml penicillin-streptomycin mix (Bio-Whittaker) at 37°C in 5% CO2. The KCL22-R cell line was further supplemented with 1µM imatinib (kindly provided by Novartis Pharma, Basel, Switzerland) every 48 h [20].

Reagents

K562 cells were treated with 20 µM etoposide (Sigma-Aldrich, St Louis, MO, USA), 10 µg/ml camptothecin (Sigma-Aldrich), 5 µM staurosporine (Sigma-Aldrich).
The KCL22-S and KCL22-R cell lines were incubated in the presence of either 5 μM imatinib, 400 nM nilotinib (Novartis Pharma), or 3 nM dasatinib (Bristol-Myers Squibb Company Princeton, New Jersey, USA).

To inhibit different signaling pathways, K562 cells were treated with either 1 μM imatinib (Novartis Pharma), 30 μM LY294002 (Calbiochem, Merck KgaA, Darmstadt, Germany), 10 μM NVP-BEZ235 (Novartis Pharma), 50 ng/ml rapamycin (Cell Signalling Technology, Beverly, MA, USA) or 1 μM everolimus (Sigma-Aldrich). To investigate ZNF224 mRNA stability, cells were treated with 4 μg/ml actinomycin D (Sigma-Aldrich).

Samples from CML patients and healthy donors

After ethical approval and informed consent, umbilical cord blood samples from mothers giving birth to normal, full term infants, and bone marrow (BM) aspirates from 10 adult patients with BCR-ABL positive CP-CML at diagnosis, were collected after signed informed consent. CD34+ cells were enriched as described [33, 34]. CD34+ cell purity was always more than 90% as determined by flow cytometric analysis (data not shown). Peripheral blood (PB) mononuclear cells from 30 adult patients with BCR-ABL positive chronic phase chronic myeloid leukaemia (CP-CML) and 17 healthy donors (HDs) were collected after approval by the Institutional Review Board (IRB) of the University of Naples Federico II. Patients were enrolled from July 2012 in the Division of Hematology at University of Naples Federico II, and treated with the standard dose of imatinib (400 mg/d) as a first-line therapy. In particular, for retrospective analysis, we selected 15 consecutive optimal responding patients and 15 warning/failure patients [23]. PB samples were available from the patients at diagnosis and at the third month of therapy.

RNA isolation, reverse transcription and real-time PCR

Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 1 μg of RNA was reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen), according to the manufacturer’s protocol. To analyze the expression levels of ZNF224 mRNA in K562 cells treated with imatinib, etoposide, camptothecin, staurosporine, and actinomycin D and in KCL22-S and KCL22-R cells treated with imatinib, dasatinib and nilotinib, real-time PCR was carried out in a Real-Time CFX 69 System (Bio-Rad, Berkeley, CA, USA) using the SYBR Green I Master Mix (Bio-Rad) and specific primers for ZNF224 [13]; β2-microglobulin (primer sequences: Fw 5’-cccgtggccttagctgtgct-3’, Rev 5’-gacctggatgcgtaacctaggagtgggttcgaaccc-3’). The amplified fragment was cloned into KpnI/ HindIII sites of a pGL3-basic vector.

Transient transfection and luciferase-reporter assays

KG1 cells were transiently transfected by electroporation using a Bio-Rad Gene Pulser II System (Bio-Rad). 10 μg of pcDNA3-p210BCR/ABL (kindly provided by Dr. Thoas Fioretos) or 10 μg of pcDNA3 empty vector used as control were electroporated in 9x10^6 KG1 cells. A plasmid encoding enhanced green fluorescent protein (eGFP) was used to determine transfection efficiency. The electroporation conditions were as follows: 300 V, 960 μF, using a 0.4-cm gapped cuvette (Bio-Rad).
for each condition. After 48h, cells were counted and stained for viability using trypan blue solution (Sigma-Aldrich).

K562 cells were transiently transfected using HiPerfect Reagent (Qiagen) with either 0.5 µg of a luciferase reporter plasmid containing the proximal ZNF224 promoter (PromZNF224) or with 0.5 µg of the empty pGL3-luciferase vector (pGL3-Luc), used as control. Cells were co-transfected with 0.25 or 0.5 µg of WT1(-KTS) expression plasmid, or with the pcDNA3 (0.5 µg) used as negative control. After 24h, the transfected cells were treated with either 1 µM imatinib for 24 or 48h, or with DMSO for 48h. To normalize the luciferase assays a pRL-CMV plasmid (50 ng) coding for the renilla luciferase was used. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega Corporation, WI, USA) according to the manufacturer’s instructions.

### Lentiviral transduction of K562 cells

Two lentiviral shRNAs targeting WT1 pLKO.1/WT1 shRNA 1 (TRCN0000040066) (Open Biosystems, Huntsville, AL, USA) and pLKO.1/WT1 shRNA 2 (TRCN0000040067) or one GFP shRNA used as negative control (both kindly provided by A. Sweet-Cordero, Stanford University, Stanford, CA) were used for lentiviral transduction of K562 cells. Lentiviral particles were harvested after calcium phosphate transfection of HEK293T cells with the respective shRNA constructs, gag-pol and the RD114 envelope genes. For lentiviral transduction of K562 cells, lentiviral particles were added to K562 cells plated at a density of 2.5x10^4/well in 12-well plates and were exposed to imatinib, etoposide (Sigma-Aldrich), camptothecin (Sigma-Aldrich), or staurosporine (Sigma-Aldrich). The relative amount of apoptotic cells was determined by co-staining cells with annexin V-APC (4',6-diamidino-2-phenylindole) (D9564, Sigma-Aldrich), camptothecin (Sigma-Aldrich), or staurosporine (Sigma-Aldrich). The percentage of cells within the population positive for DAPI and positive for annexin V was determined by co-staining cells with annexin V-APC (4',6-diamidino-2-phenylindole) (D9564, Sigma-Aldrich) as previously described (13).

### Analysis of viability and apoptosis by flow cytometry

K562 cells were plated at a density of 2.5x10^4/well in 12-well plates and were exposed to imatinib, etoposide (Sigma-Aldrich), camptothecin (Sigma-Aldrich), or staurosporine (Sigma-Aldrich). The relative amount of apoptotic cells was determined by co-staining cells with annexin V-APC (550474, BD Pharmingen, San Jose, CA, USA) and DAPI (4',6-diamidino-2-phenylindole) (D9564, Sigma-Aldrich) as previously described (13).

### Western blot analysis

Total protein extracts were obtained as previously described [13], resolved with SDS-PAGE and transferred to Hybond membranes (Amersham Biosciences, NJ, USA). Non-specific binding sites were blocked for 2 h with 5% milk in Tris-Tween buffered saline (tTBS) (5 mM Tris pH 7.5, 15 mM NaCl, 0.1% Tween-20), washed three times with tTBS and incubated with antibodies. For the primary antibodies anti-GAPDH (7-B) (Santa Cruz Biotechnology, 1:1000), anti-β-Tubulin (Upstate, Lake Placid, NY, 1:2000), the secondary antibody goat-anti-mouse IgG (H+L)-HRP conjugated (BioRad 170-6516, 1:3000) was used. For the primary antibodies anti-WT1 (C19) (Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:500), anti-Akt (Cell Signaling Technology, Beverly, MA, USA, 1:1000), anti-Phospho-Akt Ser473 (Cell Signaling Technology, 1:1000), anti-p70 S6 Kinase (49D7) (Cell Signaling Technology, 1:1000), anti-Phospho-p70 S6 Kinase Thr389 (108D2) (Cell Signaling Technology, 1:1000), the secondary antibody goat-anti-rabbit IgG (H+L)-HRP conjugated (BioRad170-6515, 1:3000) was used. For detection, an ECL western blot detection system (Amersham Biosciences) was used. ZNF224 protein analysis was performed using the anti-ZNF224 (T3) antibody (Rabbit polyclonal antibody) (1) as previously described [13].
ACKNOWLEDGMENTS

We are grateful to Prof. T. Russo (Naples, Italy) for helpful discussions and suggestions. Dr. G. Montano wishes to thank the Federation of European Biochemical Societies (FEBS) for a short-term fellowship. We also thank Dr Thoas Fioretos (Lund, Sweden) for providing us with the pcDNA3-p210BCR/ABL plasmid and Novartis Pharma for providing nilotinib and NVP-BEZ235.

FUNDING

This work was supported by grants from POR Campania FSE 2007-2013, Project CREMe, POR Campania 2012-2015, Project OcKey, the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Royal Fysiographic Society, Blodsjukas förening, and the Gunnar Nilsson Cancer Foundation.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Medugno L, Costanzo P, Lupo A, Monti M, Florio F, Pucci P, Izzo P. A novel zinc finger transcriptional repressor, ZNF224, interacts with the negative regulatory element (AldA-NRE) and inhibits gene expression. FEBS Letters 2003; 534: 93-1002.
2. Medugno L, Florio F, De Cegli R, Grosso M, Lupo A, Costanzo P, Izzo P. The Kruppel-like zinc finger protein ZNF224 represses aldolase A gene transcription by interacting with the KAP-1 corepressor protein. Gene 2005; 359: 35-43.
3. Sripathy SP, Stevens J, Schultz DC. The KAP1 corepressor functions to coordinate the assembly of de novo HP1 demarcated microenvironments of heterochromatin required for KRAB Zinc Finger Protein-mediated transcriptional repression. Mol. Cell Biol. 2006; 26: 8623-8638.
4. Cesaro E, De Cegli R, Medugno L, Florio F, Grosso M, Lupo A, Izzo P, Costanzo P. The Kruppel-like zinc finger protein ZNF224 recruits the arginine methyltransferasePRMT5 on the transcriptional repressor complex of the aldolase A gene. J. Biol. Chem. 2009; 284: 32231-32230.
5. Florio F, Cesaro E, Montano G, Izzo P, Miles C, Costanzo P. Biochemical and functional interaction between ZNF224 and ZNF255, two members of the Kruppel-like zinc-finger protein family and WT1 protein isoforms. Hum. Mol. Genet. 2010; 19: 3544-3556.
6. Yang L, Han Y, Suarez SF, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868-876.
7. Miwa H, Beran M, Saunders GF. Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405-409.
8. Huff V. Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nature Reviews Cancer 2011; 11: 111-121.
9. Loeb DM. WT1 influences apoptosis through transcriptional regulation of Bcl-2 family members. Cell Cycle 2006; 5:1249-1253.
10. Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T, Asada M, Jomgeow T, Aoyagi S, Nakano Y, Tamaki H, Sakaguchi N, Shirakata T. et al. Antiapoptotic function of 17AA(+)WT1 (Wilms’ tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 2006; 25: 4217-4229.
11. Simpson LA, Burwell EA, Thompson KA, Shahnaz S, Chen AR, Loeb DM. The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood 2006; 107: 4695-4702.
12. Cesaro E, Montano G, Rosati A, Crescitiello R, Izzo P, Turco MC, Costanzo P. WT1 protein is a transcriptional activator of the antiapoptotic bag3 gene. Leukemia 2010; 24:1204-1206.
13. Montano G, Cesaro E, Fattore L, Vidovic K, Palladino C, Crescitiello R, Izzo P, Turco MC, Costanzo P. Role of WT1-ZNF224 interaction in the expression of apoptosis-regulating genes. Hum. Mol. Genet. 2013; 22: 1771-1782.
14. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
15. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pellici PG, Arlinghaus R, Pacion D. The Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway. EMBO J. 1994; 13: 764-773.
16. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987; 328: 342-344.
17. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
18. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter DJ. Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83:1179-1187.
19. Svensson E, Vidovic K, Lassen C, Richter J, Olofsson T, Fioretos T, Gullberg U. Deregulation of the Wilms’ tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells. Leukemia 2007; 21: 2485-2494.
20. Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D. et al. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia.
Chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood 2011; 118: 3634-3644.

21. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 1995; 15: 5531-5541.

22. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 2005; 5: 172-183.

23. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Clark RE, Cortes JE, Guilhot F, Jhorth-Hansen H, Hughes TP, Kantarjian HM. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872-884.

24. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukaemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res. 2005; 65: 9436-944.

25. Essafi A, Fernández de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS, Medema RH, Lam EW. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 2005; 24: 2317-2329.

26. Casolari DA, Makri M, Yoshida C, Muto A, Igarashi K, Melo JV. Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5. Leukemia 2013; 27: 409-415.

27. Vidovic K, Svensson E, Nilsson B, Thuresson B, Olofsson T, Lennartsson A, Gullberg U. Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. Leukemia 2010; 15: 249-255.

28. Ryan G, Steele-Perkins V, Morris JF, Rauscher FJ 3rd, Dressler GR. Repression of Pax-2 by WT1 during normal kidney development. Development 1995; 121: 867-875.

29. Dehbi M, Ghahremani M, Lechner M, Dressler G, Pelletier J. The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1). Oncogene 1996; 13: 447-453.

30. Discenza MT, He S, Lee TH, Chu LL, Bolon B, Goodyer P, Eccles M, Pelletier J. WT1 is a modifier of the Pax2 mutant phenotype: cooperation and interaction between WT1 and Pax2. Oncogene 2003; 22: 8145-8155.

31. Milojkovic D, Apperley J. Mechanisms of Resistance to Imatinib and Second-Generation Tyroisine Inhibitors in Chronic Myeloid Leukemia. Clin. Cancer. Res. 2009; 15: 7519-7527.

32. Quintás-Cardama A, Cortes J. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood 2009; 113: 1619-1630.

33. Svedberg H, Richter J, and Gullberg U. Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34+ progenitor cells. Leukemia 2001; 15: 1914-1922.

34. Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, Raia M, Pagliuca S, Pugliese N, Risiatano AM, Picardi M, Luciano L, Saglio G. et al. Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. Leuk. Res. 2014 ; 38:236-242.

35. Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp. Hematol. 2002; 30: 503-512.

36. Gabert J, Beillard E, Van der Velden VH, Bi W, Grimwade D, Pullisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, De Micheli D. et al. Standardization and quality control studies of ‘real time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia-A Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.

37. Hughes T, Deininger M, Hochhaus A, Brandford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.

38. Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K. et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330-3338.

39. Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, Hehlmann R, Branford S, Saglio G, Hochhaus A. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957-1963.